These results suggest that higher DHCR7 expression may contribute to reduced sensitivity to tumor immunotherapy, highlighting the potential for combining DHCR7 inhibitors with therapeutic strategies in future cancer treatments. The gene discussed is DHCR7; the disease is neoplasm.